Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Frequently asked questions
What sector does Zealand Pharma A/S (ZEAL) operate in?
Zealand Pharma A/S belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Zealand Pharma A/S (ZEAL) current stock price?
As of the latest data, Zealand Pharma A/S stock price is DKK 223.40, with a previous close of DKK 223.30. Zealand Pharma A/S gained DKK 0.10 in the last trading session, representing a 0.04% increase.
What is Zealand Pharma A/S (ZEAL) current market capitalization?
Zealand Pharma A/S market cap is approximately 15.07 billion.
What is Zealand Pharma A/S (ZEAL) Earnings Per Share (EPS)?
The trailing EPS is DKK 39.16, and the forward EPS is DKK 7.30.
What is Zealand Pharma A/S (ZEAL) Price-to-Earnings (P/E) ratio?
Zealand Pharma A/S current P/E ratio is 5.7, with a forward P/E of 30.61.
What is Zealand Pharma A/S (ZEAL) EBITDA?
Zealand Pharma A/S EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 3.87 billion.
Does Zealand Pharma A/S (ZEAL) pay dividends?
No. Zealand Pharma A/S does not pay a dividend.
How did Zealand Pharma A/S (ZEAL) perform in its most recent earnings report?
In the last report (June 30, 2026), Zealand Pharma A/S posted an EPS surprise of 159.33% and a revenue surprise of 85.7%.
When is Zealand Pharma A/S (ZEAL) next earnings report?
Zealand Pharma A/S is expected to release its next earnings report on September 30, 2026.
What is Zealand Pharma A/S (ZEAL) beta (volatility) score?
Zealand Pharma A/S has a beta of 0.593, indicating lower volatility than the overall market.
